Relevant Publications

Select Publications by Athersys and Collaborators

Maziarz RT, Devos T, Bachier CR, Goldstein SC, et al.: Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial. Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8.

Lang BT, Cregg JM, DePaul MA, Tran AP, et al.: Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury. Nature. 2015 Feb 19;518(7539):404-8.

Filous AR, Tran A, Howell CJ, Busch SA, et al.: Entrapment via synaptic-like connections between NG2 proteoglycan+ cells and dystrophic axons in the lesion plays a role in regeneration failure after spinal cord injury. J Neurosci. 2014 Dec 3;34(49):16369-84.

Andrews PW, Cavagnaro J, Deans RJ, Feigal E, et al.: Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nat Biotechnology. 2014 Nov;32(11):1166.

La Francesca S, Ting AE, Sakamoto J, Rhudy J, et al.: Multipotent adult progenitor cells decrease cold ischemic injury in ex vivo perfused human lungs: an initial pilot and feasibility study. Transplant Res. 2014 Nov 1;3(1):19.

Rojas M, Cárdenes N, Kocyildirim E, Tedrow JR, et al.: Human adult bone marrow-derived stem cells decrease severity of lipopolysaccharide-induced acute respiratory distress syndrome in sheep. Stem Cell Res Ther. 2014 Mar 26;5(2):42.

Eggenhofer E, Popp FC, Mendicino M, Silber P, Van’t Hof W, et al.: Heart Grafts Tolerized Through Third-Party Multipotent Adult Progenitor Cells Can Be Retransplanted to Secondary Hosts With No Immunosuppression. Stem Cells Translational Medicine 2013;2:595–606

Reading JL, Sabbah S, Busch S, Tree TI: Mesenchymal stromal cells as a means of controlling pathological T-cell responses in allogeneic islet transplantation. Curr Opin Organ Transplant 2013 Feb;18(1):59-64.

Ryu JC, Davidson BP, Xie A, Qi Y, Zha D, Belcik JT, et al.: Molecular Imaging of the Paracrine Proangiogenic Effects of Progenitor Cell Therapy in Limb Ischemia. Circulation. 2013 Jan 10. [Epub ahead of print]

Bravery CA, J. Carmen, T. Fong, W. Oprea, et al.: Potency Assay Development for Cellular Therapy Products; An ISCT Review of the Requirements and Experiences in the Industry. Cytotherapy 2013 15: 9-19

Ting AE, Sherman W: Allogeneic stem cell transplantation for ischemicmyocardial dysfunction. Curr Opin Organ Transplant. 2012 Dec;17(6):675-80.

Vaes B, Van’t Hof W, Deans RJ, Pinxteren J: Application of MultiStem allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol. 2012;3:345. Epub 2012 Nov 27.

Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, et al.: Human multipotent adult progenitor cells are non-immunogenic and exert potent immunomodulatory effects on alloreactive T cell responses. Cell Transplant. 2012 Oct 1. [Epub ahead of print]

Walker PA, Bedi SS, Shah SK, Jimenez F, et al.: Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: modulation of the resident microglia population. J Neuroinflammation. 2012 Sep 28;9:228.

Lehman N, Cutrone R, Raber A, Perry R, et al.: Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy. Sep;14(8):994-1004 (2012)

Medicetty S, Wiktor D, Lehman N, Raber A, et al.: Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant. 21(6):1109-20. Epub 2011 Oct 14 (2012)

Nan Z, Shekels L, Ryabinin O, et al.: Intra-cerebroventricular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of Mucopolysaccharidosis type I (MPS-I). Cell Transplant [epub ahead of print] (2012)

Penn MS, Ellis S, Gandhi S, et al.: Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res 110(2):304-11 (2012)

Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J et al.: Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). J Transl Med 9:124; 2011.

Busch SA,van Crutchen STJ, Deans RJ, Ting AE: Mesenchymal Stromal Cells as a Therapeutic Strategy to Support Islet Transplantation in Type 1 Diabetes Mellitus. Cell Medicine, Volume 2, Number 2, 2011, pp. 43-53(11). ingentaconnect Link

Busch SA, Hamilton JA, Horn KP, Cuascut FX, et al.: Multipotent adult progenitor cells prevent macro-phage mediated axonal dieback and promote regrowth after spinal cord injury. Journal of Neuroscience 31(3):944-953 (2011)

DimomeletisI, Deindl E, Zaruba M, Groebner M, Zahler S. et al.: Assessment of human MAPCs for stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice. Experimental Hematology 38(11):1105-14 (2010)

Aranguren XL, Pelacho B, Peñuelas I, Abizanda G, Uriz M, et al.: MAPC transplantation confers a more durable benefit than ACC133+ cell transplantation. Cell Transplant 2010 Aug 17 (E pub ahead of print)

Walker PA, Shah SK, Jimenez F, Gerber MH, Xue H, et al.: Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: preserving the blood brain barrier via an interaction with splenocytes. Experimental Neurology 225:341–352 (2010)

Mays RW, Borlongan CV, Yasuhara T et al.: Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. J Exp Stroke Transl Med 3(1): 34-46 (2010)

Jameel MN, Li Q, Qiang X et al.: Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction. Am J Physiol Heart Circ Physiol 298(5):H1348-56. (2010)

Kovacsovics-Bankowski M, Streeter PR, Mauch KA et al.: Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol. 255(1-2):55-60 (2009)

Wang X, Jameel MN, Li Q, Mansoor A, Qiang X, Swingen C, Panetta C, Zhang J. Stem cells for myocardial repair with use of a transarterial catheter. Circulation. 2009 Sep 15;120 (11 Suppl):S238-46

Highfill SL, Kelly RM, O'Shaughnessy MJ et al.: Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming Blood 114(3): 693–701 (2009)

Boozer S, Lehman N, Lakshmipathy U et al.: Global characterization and genomic stability of human MultiStem, a multipotent adult progenitor cell. J Stem cells 4(1):17-28 (2009)

Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 40(2):510-5. (2009)

Kovacsovics-Bankowski M., Mauch K., Raber, A., et al.: Preclinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 10:7,730 — 742 (2008)

Yasuhara T, Hara K, Maki M, Mays RW et al.: Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J Cereb Blood Flow Metab 28 (11):1804-10. (2008)

Hess DC, and Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother (8): 1193–1201 (2008)

Mays R, Van't Hof W, Deans R, et al. Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin. Biol. Ther. 7(2):173-184 (2007)

Verfaillie CM, Blazar B, Weismann IL, et al. Hematopoetic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoetic stem cells. Journal of Experimental Medicine. 22;204(1):129-39 (2007)

Van't Hof W, Mal N, Raber A, et al. Multipotent adult progenitor cells. Contemporary Cardiology: Stem Cells and Myocardial Regeneration. Penn MS(Ed.) Humana Press, Inc., MA, USA. 2006: 39-50.

Breyer A, Estharubadi N, Oki M, et al. Multipotent Adult Progenitor Cell(MAPC) isolation and culture procedures. Experimental Hematology 34(11): 1596-601 (2006)

Yasuhara T, Matsukawa N, Yu G et al. Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell Transplant. 2006 15(3):231-238.

Verfaillie CM, Miler RF, Chen A, et al. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proceedings of the National Academy of Sciences Early Edition. 2003; 10.1073/1834196100.

Keene CD, Ortiz-Gonzalez XR, Jiang Y, Largaespada DA et al.: Neural differentiation and incorporation of bone marrow-derived multipotent adult progenitor cells after single cell transplantation into blastocyst stage mouse embryos. Cell Transplant. 12(3):201-13 (2003)

Verfaillie CM, Marker PH, Koodie L, et al. Origin of endothelial progenitors in human postnatal bone marrow. Journal of Clinical Investigation. 2002; 109:337-346.

Verfaillie CM, Hu WS, Johnson S, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. Journal of Clinical Investigation. 2002; 109:1291-1302.

Verfaillie LM, Reyes M, Jiang Y, et al. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle and brain. Experimental Hematology. 2002; 30:896-904.


Other Relevant Papers

Gil Van Bokkelen, Manal Morsy, Toshi-hiko Kobayashi.: Demographic Transition, Health Care Challenges, and the Impact of Emerging International Regulatory Trends With Relevance to Regenerative Medicine. Curr Stem Cell Rep 23 May 2015; DOI 10.1007/s40778-015-0013-5

Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW: Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunology and Cell Biology 91, 32-39; doi:10.1038/icb.2012.64 (2013)

Leistner DM, Zeiher AM. Novel avenues for cell therapy in acute myocardial infarction. Circ Res 110(2):195-7 (2012)

Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 17(7):796-808 (2011)

Beltrami AP, Cesselli D, Bergamin N, et al. Culture of multipotent cells from human tissues. Blood; online publication, May 24, 2007.

De Coppi P, Bartsch G Jr, Diddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25(1):100-106 (2007)

Anjos-Afonso F, Bonnet D. Non-hematopoietic/endothelial SSEA-1 pos cells defines the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood. 109(3):1298-1306 (2007)

Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL)CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia. 20(5):857-869 (2006)

Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular(HUCPV) cells: a source of mesenchymal progenitors.

Stem Cells. 23(2):220-229 (2005)

Yoon YS, Wecker A, Heyd L et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 115(2):326-338 (2005)

D'Ippolito G, Diabira S, Howard GA et al. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J. Cell Sci. 117(Pt 14):2971-2981 (2004)

Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. 200(2):123-135 (2004)


Select Publications by Athersys and Collaborators

Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, et al. Investigation of 4-piperidinols as novel H3 antagonists. Bioorg Med Chem Lett 20(21):6246-9. (2010)

Tuney LN, Robarge MJ, Gleason E, Song J, Murphy SM, et al. 3-Indolyl sultams as selective CRTH2 antagonists. Bioorg Med Chem Lett 20(11):3287-90. (2010)

Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One 3(12):e3858 (2008)

Murphy SM, Palmer M, Poole MF, Padegimas L, Hunady K, Danzig J, Gill S, Gill R, Ting A, Sherf B, Brunden K and Stricker-Krongrad A. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods. 54:42-55 (2006)

Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR, and Bennani YL. The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists. Bioorganic Med. Chem. Letters.16:2891-2894 (2006)

Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR and Bennani YL. The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist. Bioorganic Med. Chem. Letters. 16:4130-4134 (2006)

Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, et al. Development of homogeneous high affinity agonist binding assays for 5HT-2 receptor subtypes. Assay Drug Dev Technol. 3(6):649-59 (2005)

Brunden KR, Sherf BA and Harrington JJ. The Application of RAGE and GECKO in Cell-based Target Discovery Screens. Pharmacogenomics. 6:383-392 (2005)

Song J, Doucette C, Hanniford D, Hunady K, Wang N, Sherf B, Harrington JJ, Brunden KR and Stricker-Krongrad A. Generation of Cell Lines for Drug Discovery Through Random Amplification of Gene Expression (RAGE): Application to the Human Histamine H3 Receptor. Assay and Drug Development Technol. 3:309-318 (2005)

Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, et al. Identification of a novel extracellular cation-sensing G-protein coupled receptor. J Biol Chem. 280(48):40201-9 (2005)

Jackson PD, Harrington JJ. High throughput target discovery using cell-based genetics. Drug Discov Today 10(1):53-60 (2005)

Anderson JT, Ting AE, Boozer S, Brunden KR, Danzig J, Dent T, Harrington JJ, Murphy SM, Perry R, Raber A, Rundlett SE, Wang J, Wang N, and Bennani YL. The discovery of S-phase arresting agents derived from noscapine. J. Med. Chem. 48:2756-2758 (2005)

Robarge MJ, Bom DC, Tumey LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ and Bennani YL. Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists. Bioorganic Med. Chem. Letters 15(6):1749-1753 (2005)

Tumey LN, Bom D, Huck B, Gleason E, Wang J, Silver D, Brunden KR, Boozer S, Rundlett S, Sherf B, Harrington J, Murphy S, Dent T, Leventhal C, Bailey A, and. Bennani, YL. The identification and optimization of a N-hydroxy urea series of Flap Endonuclease 1 inhibitors. Bioorganic & Med. Chem. Letters. 15:277-281 (2004)

Tumey LN, Huck B, Gleason E, Wang J, Silver D, Brunden KR, Boozer S, Rundlett, S, Sherf, B, Murphy S, Harrington J, Dent T, Leventhal C, Bailey A, and Bennani, YL. The identification and optimization of 2,4-diketobutyric acids as Flap Endonuclease 1 inhibitors. Bioorganic & Med. Chem. Letters. 14:4915-4918 (2004)

Jin G, Klika A, Callahan M, Faga B, Danzig J, et al. Identification of a human NF-κB-activating protein TAB3. Proceedings of the National Academy of Sciences. 101.7:2028-33 (2004)

Harrington J, Brunden KR. Drug screening in the genomics era. Current Drug Discovery. 2002; Jan:17-20.

Other Relevant Papers

Hajjo R, Grulke CM, Golbraikh A, Setola V, Huang XP, Roth BL, Tropsha A. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvuloptahic compounds among common drugs. J Med Chem. 11;53(21):7573-86 (2010)

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, and Pezzoli G. regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther. 2010 Jun 11 [Epub ahead of print]

Huang XP, Setola V, Yadav PN, Allen JA, and Rogan SC et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine (2B) receptor agonists: implications for dug safety assessment. Mol Pharmacol 76(4):710-22 (2009)

Roth BL. Drugs and valvular heart disease. N Engl J Med. 356;1: 6 – 9 (2007)

Schade R, Andersoh F, et al. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 356;1:29 – 38 (2007)

Zanettini R, Antonini A, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 356;1:39 – 46 (2007)

Van der Goot H, Timmerman H. Selective ligands as tools to study histamine receptors. Eur J Med Chem. 35:5 – 20 (2000)